Odyssey Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
2.3%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$4.55next fiscal year
Monitoring Framework
Key Performance Indicators
OD-001 Phase 2a Ulcerative Colitis Clinical Remission Rate Annually27.0%Target: Demonstrate competitive efficacy compared to standard of care and advanced therapies
OD-001 Phase 2a Ulcerative Colitis Clinical Response Rate Annually61.0%Target: Demonstrate robust clinical response in moderate-to-severe patients
Cash Runway QuarterlyTarget: Fund operations into the second half of 2028
Watch Items
- OD-001 Phase 2b monotherapy trial initiationTrigger: Initiation in the second half of 2026Action: Monitor patient enrollment and clinical site activation
- OD-001 Phase 2a combination trial with vedolizumab initiationTrigger: Initiation in the second half of 2026Action: Track regulatory approvals and protocol alignment with Takeda's Entyvio
- OD-002 SLC15A4 inhibitor CTA filingTrigger: Filing in the second half of 2026Action: Verify completion of IND-enabling studies and submission of clinical trial application
Research as of 24 Jul 2026